Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELCNYSE:CORBFNASDAQ:CSTLNASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$10.86+0.4%$10.14$7.58▼$19.77$410.93M0.56299,087 shs207,917 shsCORBFGlobal Cord Blood$1.05-3.7%$0.95$0.25▼$2.00$127.63M-0.68157,555 shs3,000 shsCSTLCastle Biosciences$16.32-4.2%$19.59$15.70▼$35.84$471.19M1.19402,698 shs439,544 shsPSNLPersonalis$4.82-6.2%$3.71$1.14▼$7.20$425.73M1.831.00 million shs589,183 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+0.37%+6.59%+11.38%-13.95%-35.70%CORBFGlobal Cord Blood0.00%-3.67%+61.54%0.00%-16.00%CSTLCastle Biosciences-4.17%-4.28%-17.95%-40.89%-31.74%PSNLPersonalis-6.23%+0.10%+48.77%-3.41%+217.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELCCelcuity1.9148 of 5 stars3.61.00.00.02.52.50.0CORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACSTLCastle Biosciences2.1452 of 5 stars3.52.00.00.02.62.50.0PSNLPersonalis4.1107 of 5 stars3.53.00.04.22.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.14Buy$30.17177.78% UpsideCORBFGlobal Cord Blood 0.00N/AN/AN/ACSTLCastle Biosciences 3.00Buy$37.50129.78% UpsidePSNLPersonalis 3.00Buy$8.0065.98% UpsideCurrent Analyst Ratings BreakdownLatest CORBF, CSTL, PSNL, and CELC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/10/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/1/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.003/28/2025CSTLCastle BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$30.003/17/2025PSNLPersonalisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.002/28/2025CSTLCastle BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$36.00 ➝ $37.002/28/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$5.48 per shareN/ACORBFGlobal Cord Blood$196.12M0.65$0.75 per share1.40N/A∞CSTLCastle Biosciences$347.08M1.36N/AN/A$14.54 per share1.12PSNLPersonalis$85.69M4.97N/AN/A$2.64 per share1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$63.78M-$2.81N/AN/AN/AN/A-62.66%-39.78%N/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/ACSTLCastle Biosciences-$57.47M-$0.1981.60N/AN/A1.95%1.47%1.27%N/APSNLPersonalis-$108.30M-$1.29N/AN/AN/A-104.52%-66.07%-41.34%N/ALatest CORBF, CSTL, PSNL, and CELC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/A2/27/2025Q4 2024PSNLPersonalis-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity0.6510.3510.36CORBFGlobal Cord BloodN/AN/AN/ACSTLCastle Biosciences0.027.787.64PSNLPersonalisN/A4.684.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%CORBFGlobal Cord BloodN/ACSTLCastle Biosciences92.60%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipCELCCelcuity15.77%CORBFGlobal Cord Blood0.50%CSTLCastle Biosciences7.20%PSNLPersonalis3.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4037.84 million31.27 millionOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableCSTLCastle Biosciences54028.87 million25.99 millionOptionablePSNLPersonalis40088.33 million67.75 millionOptionableCORBF, CSTL, PSNL, and CELC HeadlinesRecent News About These Companies8,160,734 Shares in Personalis, Inc. (NASDAQ:PSNL) Purchased by Lightspeed Management Company L.L.C.May 14 at 6:30 AM | marketbeat.comWhat is HC Wainwright's Estimate for Personalis Q2 Earnings?May 13 at 1:47 AM | marketbeat.comHC Wainwright Has Negative Outlook of Personalis Q2 EarningsMay 13 at 1:47 AM | americanbankingnews.comPersonalis (NASDAQ:PSNL) Price Target Raised to $9.00 at HC WainwrightMay 10, 2025 | americanbankingnews.comHC Wainwright Boosts Personalis (NASDAQ:PSNL) Price Target to $9.00May 9, 2025 | marketbeat.comCompanies Like Personalis (NASDAQ:PSNL) Are In A Position To Invest In GrowthMay 8, 2025 | finance.yahoo.comPersonalis Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comPersonalis, Inc. (PSNL) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comPersonalis (PSNL) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comMarshall Wace LLP Has $405,000 Holdings in Personalis, Inc. (NASDAQ:PSNL)May 6, 2025 | marketbeat.com134,000 Shares in Personalis, Inc. (NASDAQ:PSNL) Purchased by 683 Capital Management LLCMay 4, 2025 | marketbeat.comPersonalis (PSNL) to Release Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comPersonalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer StudyApril 29, 2025 | finance.yahoo.comWhy Personalis, Inc.’s (PSNL) Stock Is Down 5.21%April 29, 2025 | aaii.comWalleye Capital LLC Sells 154,940 Shares of Personalis, Inc. (NASDAQ:PSNL)April 29, 2025 | marketbeat.comPersonalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer StudyApril 28, 2025 | businesswire.comJump Financial LLC Purchases New Position in Personalis, Inc. (NASDAQ:PSNL)April 26, 2025 | marketbeat.comPersonalis to Announce First Quarter 2025 Financial ResultsApril 23, 2025 | finance.yahoo.comIs Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23, 2025 | msn.comPersonalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence DetectionApril 22, 2025 | businesswire.comPersonalis, Inc. (NASDAQ:PSNL) is Blue Water Life Science Advisors LP's 6th Largest PositionApril 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORBF, CSTL, PSNL, and CELC Company DescriptionsCelcuity NASDAQ:CELC$10.86 +0.04 (+0.37%) As of 05/14/2025 04:00 PM EasternCelcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Global Cord Blood NYSE:CORBF$1.05 -0.04 (-3.67%) As of 05/14/2025 09:31 AM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Castle Biosciences NASDAQ:CSTL$16.32 -0.71 (-4.17%) As of 05/14/2025 04:00 PM EasternCastle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Personalis NASDAQ:PSNL$4.82 -0.32 (-6.23%) As of 05/14/2025 04:00 PM EasternPersonalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
